Consensus document recommends discussion at follow-ups for T2D patients
Cardiologists should consider adding a glucose-lowering drug proven to have cardiovascular benefits for all their type 2 diabetes (T2D) patients, according to consensus recommendations from the American College of Cardiology (ACC).